항암제 경제성평가에서 점증적 비용-효과비와 의사결정
Hoe Sang Kim, 고수경, 강혜영 et al. · The Journal of Health Technology Assessment · 2014
Cited by 1 works. doi:10.34161/johta.2014.2.1.010
Authors
References
- National Institute for Clinical Excellence and its value judgments
- Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs
- Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold
- Cost-Effectiveness Analysis and the Consistency of Decision Making
- International survey on willingness‐to‐pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?
- Assessing the economic challenges posed by orphan drugs
- Quality, Innovation, and Value for Money
- The Role of Value for Money in Public Insurance Coverage Decisions for Drugs in Australia: A Retrospective Analysis 1994-2004
- Drugs for exceptionally rare diseases: do they deserve special status for funding?
- Drug Prices and Value for Money